Broad spectrum influenza virus resistant antagonistic peptide nasal spray preparation and application
An influenza virus and antagonism technology, applied in the directions of antiviral agents, aerosol delivery, peptides, etc., can solve the problems of long production time, shortage of raw material supply, high price, small toxic side effects, easy mass production, and high curative effect. Effect
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0090] 1. Preparation of influenza virus neuraminidase inhibitory polypeptide
[0091] a. According to the operating guidelines for peptide library screening, take A / PR / 8 / 34 (H1N1) influenza virus as the target molecule, and screen influenza virus antagonistic polypeptides from the phage random 9-peptide library;
[0092] b. Identify the neuraminidase inhibitory activity of the screened polypeptide through ELISA and in vitro NA activity inhibition experiments;
[0093] c. Sequencing the identified polypeptide and synthesizing a consensus sequence, the consensus sequence being WPKLHVHPR or SWIHHFRPH.
[0094] 2. Preparation of broad-spectrum anti-influenza virus antagonist peptide nasal spray
[0095] Put the above-prepared influenza virus neuraminidase inhibitory polypeptide, natural polysaccharide chitosan, and cytokine human interferon into a 100ml volumetric flask, and add physiological saline to the mark. Wherein, the concentration of influenza virus neuraminidase inhibi...
Embodiment 2
[0097] 1. Preparation of influenza virus neuraminidase inhibitory polypeptide
[0098] a. According to the operating guidelines for peptide library screening, take A / FM / 1 / 47 (H1N1) influenza virus as the target molecule, and screen influenza virus antagonistic polypeptides from the phage random 10 peptide library;
[0099] b. Identify the neuraminidase inhibitory activity of the screened polypeptide through ELISA and in vitro NA activity inhibition experiments;
[0100] c. Sequencing the identified polypeptides and synthesizing a consensus sequence, the consensus sequence being HWHPHSHIQP or PLQASLHHIS.
[0101] 2. Preparation of broad-spectrum anti-influenza virus antagonist peptide nasal spray
[0102] Put the above-prepared influenza virus neuraminidase inhibitory polypeptide, natural polysaccharide starch, cytokines human interferon, and human interleukin-2 into a 100ml volumetric flask, and add physiological saline to the mark. Among them, the concentration of influenza...
Embodiment 3
[0104] 1. Preparation of influenza virus neuraminidase inhibitory polypeptide
[0105] a. According to the operating guidelines for peptide library screening, take A / Sydney / 5 / 97 (H3N2) influenza virus as the target molecule, and screen influenza virus antagonistic polypeptides from the phage random 11 peptide library;
[0106] b. Identify the neuraminidase inhibitory activity of the screened polypeptide through ELISA and in vitro NA activity inhibition experiments;
[0107] c. Sequencing the identified polypeptide and synthesizing a consensus sequence, the consensus sequence is HKHNGKAWPLS or LNILSTLYKWR.
[0108] 2. Preparation of broad-spectrum anti-influenza virus antagonist peptide nasal spray
[0109] Place the above-prepared influenza virus neuraminidase inhibitory polypeptide, natural polysaccharide starch and chitosan, human interferon, human interleukin-2, and human interleukin-12 in a 100ml volumetric flask, add normal saline to scale. Among them, the concentratio...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 